Vascular abnormalities in essential hypertension

Current Pharmaceutical Design

Volumn 17, Issue 28, 2011, Pages 3039-3044

  Sudano, Isabella ^a   Roas, Susanne ^a   Noll, Georg ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Arterial stiffness; Endothelium; Essential hypertension; Nitric oxide

Indexed keywords

ANGIOTENSIN II; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; NITRIC OXIDE; PROSTACYCLIN; REACTIVE OXYGEN METABOLITE; THROMBOPLASTIN;

AORTA DISEASE; ARTERIAL STIFFNESS; ARTICLE; ATHEROSCLEROSIS; BLEEDING; BLOOD VESSEL TONE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; ENDOTHELIUM CELL; HEART INFARCTION; HUMAN; HYPERTENSION; INFLAMMATION; MORTALITY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVASCULARIZATION; SMOOTH MUSCLE FIBER; STROKE; SYSTEMATIC REVIEW (TOPIC); THROMBOSIS; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 80054081417     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211798157766     Document Type: Article

References (83)

1. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28(12): 1462-536.
2. Taddei S, Virdis A, Mattei P, Arzilli F, Salvetti A. Endotheliumdependent forearm vasodilation is reduced in normotensive subjects with familial history of hypertension. J Cardiovasc Pharmacol 1992; 20 Suppl 12: S193-5.
3. McAllister AS, Atkinson AB, Johnston GD, Hadden DR, Bell PM, McCance DR. Basal nitric oxide production is impaired in offspring of patients with essential hypertension. Clin Sci (Lond) 1999; 97(2): 141-7.
4. Millgard J and Lind L. Acute hypertension impairs endotheliumdependent vasodilation. Clin Sci (Lond) 1998; 94(6): 601-7.
5. Lacolley PJ, Lewis SJ, Brody MJ. L-NG-nitro arginine produces an exaggerated hypertension in anesthetized SHR. Eur J Pharmacol 1991; 197(2-3): 239-40.
6. Lepori M, Sartori C, Trueb L, Owlya R, Nicod P, Scherrer U. Haemodynamic and sympathetic effects of inhibition of nitric oxide synthase by systemic infusion of N(G)-monomethyl-L-arginine into humans are dose dependent. J Hypertens 1998; 16(4): 519-23.
7. Sartori C, Lepori M, Scherrer U. Interaction between nitric oxide and the cholinergic and sympathetic nervous system in cardiovascular control in humans. Pharmacol Ther 2005; 106(2): 209-20.
8. Lüscher T and Vanhoutte P. The endothelium: Modulator of cardiovascular function 1991, Boca Raton: CRC Press. 1-215.
9. Spieker LE, Flammer AJ, Luscher TF. The vascular endothelium in hypertension. Handb Exp Pharmacol 2006; (176 Pt 2): 249-83.
10. Bhagat K, Moss R, Collier J, Vallance P. Endothelial stunning following a brief exposure to endotoxin: a mechanism to link infection and infarction? Cardiovasc Res 1996; 32(5): 822-9.
11. Bhagat K and Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997; 96(9): 3042-7.
12. Boulanger C and Lüscher TF. Release of endothelin from the porcine aorta. Inhibition of endothelium-derived nitric oxide. J Clin Invest 1990; 85(2): 587-590.
13. Fichtlscherer S, Rosenberger G, Walter G, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000; 102: 1000-6.
14. Hingorani AD, Cross J, Kharbanda RK, et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000; 102: 994-9.
15. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340(2): 115-26.
16. Furchgott RF and Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
17. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327(6122): 524-6.
18. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992; 258: 1898-902.
19. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333(6174): 664-6.
20. Palmer RMJ, Rees DD, Ashton DS, Moncada S. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun 1988; 153: 1251-6.
21. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339(8793): 572-5.
22. Anderson EA and Mark AL. Flow-mediated and reflex changes in large peripheral artery tone in humans. Circulation 1989; 79(1): 93-100.
23. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 2(8670): 997-1000.
24. Brunner H, Cockcroft JR, Deanfield J, et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23(2): 233-46.
25. Panza JA, Quyyumi AA, Brush JE, Jr., Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323(1): 22-7.
26. Taddei S, Virdis A, Mattei P, et al. Hypertension causes premature aging of endothelial function in humans. Hypertension 1997; 29(3): 736-43.
27. Taddei S, Virdis A, Mattei P, et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995; 91(7): 1981-7.
28. Egashira K, Suzuki S, Hirooka Y, et al. Impaired endotheliumdependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension. Different responses to acetylcholine and substance P. Hypertension 1995; 25(2): 201-6.
29. Treasure CB, Klein JL, Vita JA, et al. Hypertension and left ventricular hypertrophy are associated with impaired endotheliummediated relaxation in human coronary resistance vessels. Circulation 1993; 87(1): 86-93.
30. Mimran A. Renal endothelial function in humans. Curr Opin Nephrol Hypertens 1998; 7(2): 149-52.
31. Deanfield J, Donald A, Ferri C, et al. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23(1): 7-17.
32. Iiyama K, Nagano M, Yo Y, et al. Impaired endothelial function with essential hypertension assessed by ultrasonography. Am Heart J 1996; 132(4): 779-82.
33. Calver A, Collier J, Moncada S, Vallance P. Effect of local intraarterial NG-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens 1992; 10(9): 1025-31.
34. Forte P, Copland M, Smith LM, Milne E, Sutherland J, Benjamin N. Basal nitric oxide synthesis in essential hypertension. Lancet 1997; 349(9055): 837-42.
35. Moncada S and Higgs EA. Arachidonate metabolism in blood cells and the vessel wall. Clin Haematol 1986; 15(2): 273-92.
36. de Nucci G, Gryglewski RJ, Warner TD, Vane JR. Receptormediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci U S A 1988; 85(7): 2334-8.
37. Harrington LS, Carrier MJ, Gallagher N, Gilroy D, Garland CJ, Mitchell JA. Elucidation of the temporal relationship between endothelial-derived NO and EDHF in mesenteric vessels. Am J Physiol Heart Circ Physiol 2007; 293(3): H1682-8.
38. Mitchell JA, de Nucci G, Warner TD, Vane JR. Different patterns of release of endothelium-derived relaxing factor and prostacyclin. Br J Pharmacol 1992; 105(2): 485-9.
39. Joannides R, Richard V, Haefeli WE, Linder L, Lüscher TF, Thuillez C. Role of basal and stimulated release of nitric oxide in the regulation of radial artery caliber in humans. Hypertension 1995; 26(2): 327-31.
40. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, structure of the receptors and their subtypes. Pharmacol Rev 1994; 46(2): 205-29.
41. Halushka PV, Mais DE, Morinelli TA. Thromboxane and prostacyclin receptors. Prog Clin Biol Res 1989; 301: 21-8.
42. Shimokawa H, Flavahan NA, Lorenz RR, Vanhoutte PM. Prostacyclin releases endothelium-derived relaxing factor and potentiates its action in coronary arteries of the pig. Br J Pharmacol 1988; 95(4): 1197-203.
43. Delpy E, Coste H, Gouville AC. Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3. Br J Pharmacol 1996; 119(3): 471-8.
44. Taddei S, Ghiadoni L, Virdis A, Buralli S, Salvetti A. Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired nitric oxide availability in essential hypertensive patients. Circulation 1999; 100(13): 1400-5.
45. Duvall WL. Endothelial dysfunction and antioxidants. Mt Sinai J Med 2005; 72(2): 71-80.
46. Edwards G, Dora KA, Gardener MJ, Garland CJ, Weston AH. K+ is an endothelium-derived hyperpolarizing factor in rat arteries. Nature 1998; 396(6708): 269-72.
47. Campbell WB and Falck JR. Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors. Hypertension 2007; 49(3): 590-6.
48. Larsen BT, Gutterman DD, Sato A, et al. Hydrogen peroxide inhibits cytochrome p450 epoxygenases: interaction between two endothelium-derived hyperpolarizing factors. Circ Res 2008; 102(1): 59-67.
49. Taddei S, Versari D, Cipriano A, et al. Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients. J Am Coll Cardiol 2006; 48(3): 508-15.
50. Faraci FM, Sobey CG, Chrissobolis S, Lund DD, Heistad DD, Weintraub NL. Arachidonate dilates basilar artery by lipoxygenasedependent mechanism and activation of K(+) channels. Am J Physiol Regul Integr Comp Physiol 2001; 281(1): R246-53.
51. Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 1994; 368(6474): 850-3.
52. Ellis A and Triggle CR. Endothelium-derived reactive oxygen species: their relationship to endothelium-dependent hyperpolarization and vascular tone. Can J Physiol Pharmacol 2003; 81(11): 1013-28.
53. Popp R, Brandes RP, Ott G, Busse R, Fleming I. Dynamic modulation of interendothelial gap junctional communication by 11,12-epoxyeicosatrienoic acid. Circ Res 2002; 90(7): 800-6.
54. Wei CM, Hu S, Miller VM, Burnett JC, Jr. Vascular actions of Ctype natriuretic peptide in isolated porcine coronary arteries and coronary vascular smooth muscle cells. Biochem Biophys Res Commun 1994; 205(1): 765-71.
55. Griffith TM. Endothelium-dependent smooth muscle hyperpolarization: do gap junctions provide a unifying hypothesis? Br J Pharmacol 2004; 141(6): 881-903.
56. Griffith TM, Chaytor AT, Edwards DH. The obligatory link: role of gap junctional communication in endothelium-dependent smooth muscle hyperpolarization. Pharmacol Res 2004; 49(6): 551-64.
57. Takase H, Moreau P, Kung CF, Nava E, Luscher TF. Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency. Effect of verapamil and trandolapril. Hypertension 1996; 27(1): 25-31.
58. Vanhoutte PM, Feletou M, Taddei S. Endothelium-dependent contractions in hypertension. Br J Pharmacol 2005; 144(4): 449-58.
59. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332(6163): 411-5.
60. Rubanyi GM and Botelho LH. Endothelins. Faseb J 1991; 5(12): 2713-20.
61. Alberts GF, Peifley KA, Johns A, Kleha JF, Winkles JA. Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop. J Biol Chem 1994; 269(13): 10112-8.
62. Zhou MS, Schulman IH, Raij L. Nitric oxide, angiotensin II, hypertension. Semin Nephrol 2004; 24(4): 366-78.
63. Ward NC and Croft KD. Hypertension and oxidative stress. Clin Exp Pharmacol Physiol 2006; 33(9): 872-6.
64. Ward NC, Hodgson JM, Puddey IB, Mori TA, Beilin LJ, Croft KD. Oxidative stress in human hypertension: association with antihypertensive treatment, gender, nutrition, lifestyle. Free Radic Biol Med 2004; 36(2): 226-32.
65. McIntyre M, Bohr DF, Dominiczak AF. Endothelial function in hypertension: the role of superoxide anion. Hypertension 1999; 34(4 Pt 1): 539-45.
66. Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003; 111(8): 1201-9.
67. Landmesser U, Spiekermann S, Preuss C, et al. Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease. Arterioscler Thromb Vasc Biol 2007; 27(4): 943-8.
68. Zalba G, San Jose G, Moreno MU, et al. Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension 2001; 38(6): 1395-9.
69. Touyz RM and Schiffrin EL. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol 2004; 122(4): 339-52.
70. Lassegue B and Griendling KK. Reactive oxygen species in hypertension; An update. Am J Hypertens 2004; 17(9): 852-60.
71. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002; 82(1): 47-95.
72. Zhang C. The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol 2008; 103(5): 398-406.
73. Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 2006; 113(5): 722-31.
74. He M, He X, Xie Q, Chen F, He S. Angiotensin II induces the expression of tissue factor and its mechanism in human monocytes. Thromb Res 2006; 117(5): 579-90.
75. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 55(13): 1318-27.
76. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27(21): 2588-605.
77. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J. 31(19): 2338-50.
78. Cecelja M and Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review. Hypertension 2009; 54(6): 1328-36.
79. Boulanger CM. Secondary endothelial dysfunction: hypertension and heart failure. J Mol Cell Cardiol 1999; 31(1): 39-49.
80. Ceriello A. Possible role of oxidative stress in the pathogenesis of hypertension. Diabetes Care 2008; 31 Suppl 2: S181-4.
81. Hermann M, Flammer A, Luscher TF. Nitric oxide in hypertension. J Clin Hypertens (Greenwich) 2006; 8(12 Suppl 4): 17-29.
82. Taddei S, Virdis A, Ghiadoni L, Salvetti A. Vascular effects of endothelin-1 in essential hypertension: relationship with cyclooxygenase-derived endothelium-dependent contracting factors and nitric oxide. J Cardiovasc Pharmacol 2000; 35(4 Suppl 2): S37-40.
83. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Endothelial dysfunction in hypertension. J Cardiovasc Pharmacol 2001; 38 Suppl 2: S11-4.